CN110742907A - Application of composition of donkey-hide gelatin and new donkey-hide gelatin in preparation of anti-aging drugs - Google Patents
Application of composition of donkey-hide gelatin and new donkey-hide gelatin in preparation of anti-aging drugs Download PDFInfo
- Publication number
- CN110742907A CN110742907A CN201911220882.1A CN201911220882A CN110742907A CN 110742907 A CN110742907 A CN 110742907A CN 201911220882 A CN201911220882 A CN 201911220882A CN 110742907 A CN110742907 A CN 110742907A
- Authority
- CN
- China
- Prior art keywords
- donkey
- hide gelatin
- new
- galactosidase
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010010803 Gelatin Proteins 0.000 title claims abstract description 81
- 229920000159 gelatin Polymers 0.000 title claims abstract description 81
- 239000008273 gelatin Substances 0.000 title claims abstract description 81
- 235000019322 gelatine Nutrition 0.000 title claims abstract description 81
- 235000011852 gelatine desserts Nutrition 0.000 title claims abstract description 81
- 239000000203 mixture Substances 0.000 title claims abstract description 19
- 230000003712 anti-aging effect Effects 0.000 title claims abstract description 18
- 239000003814 drug Substances 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 title abstract description 7
- 229940079593 drug Drugs 0.000 title description 3
- 102000005936 beta-Galactosidase Human genes 0.000 claims abstract description 35
- 108010005774 beta-Galactosidase Proteins 0.000 claims abstract description 35
- 230000001603 reducing effect Effects 0.000 claims abstract description 6
- 108010052008 colla corii asini Proteins 0.000 claims description 11
- 230000000694 effects Effects 0.000 abstract description 28
- 241000252212 Danio rerio Species 0.000 abstract description 24
- 238000010186 staining Methods 0.000 abstract description 11
- 230000002829 reductive effect Effects 0.000 abstract description 7
- 230000032683 aging Effects 0.000 abstract description 3
- 238000002474 experimental method Methods 0.000 abstract description 3
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000009471 action Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000283074 Equus asinus Species 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241001331845 Equus asinus x caballus Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000010094 cellular senescence Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 201000003725 primary thrombocytopenia Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
Abstract
The invention discloses an application of a composition of donkey-hide gelatin and new donkey-hide gelatin in preparation of an anti-aging medicament, wherein β -galactosidase is an important biological index for reflecting aging degree, after zebra fish is treated by the composition of donkey-hide gelatin and new donkey-hide gelatin, according to a β -galactosidase staining result, the activity of β -galactosidase in the zebra fish is obviously reduced, the application further discloses that the β -galactosidase in the zebra fish is reduced along with the increase of the concentration of the composition of donkey-hide gelatin and new donkey-hide gelatin in a proper concentration range and a proper proportion range, and a good descending relation is presented, the application explores through experiments to obtain an effective dose of the composition of donkey-hide gelatin and new donkey-hide gelatin to be applied to preparation of the anti-aging medicament, and a better anti-aging effect can be achieved by reducing the activity of β -galactosidase.
Description
Technical Field
The application relates to a new application of a donkey-hide gelatin composition, in particular to an application of a composition of donkey-hide gelatin and new donkey-hide gelatin in preparing an anti-aging medicament.
Background
The most remarkable characteristic of cellular senescence is that the cells still maintain metabolic activity for a long time, but lose the reactivity to mitogen and the ability to synthesize DNA due to the arrest in the G1 phase, and cannot enter the S phase.
Colla Corii Asini is solid gum prepared from dry or fresh skin of Equus asinus L. Has effects in replenishing blood, nourishing yin, moistening dryness, and stopping bleeding. Modern pharmacological research shows that the donkey-hide gelatin has the effects of enriching blood, stopping bleeding, enhancing immunity, resisting radiation, inhibiting tumor, resisting fatigue, preventing osteoporosis, promoting bone healing and the like.
The medicinal history of pigskin gelatin has been started before now. Posthan zhangzhongjing "typhoid treatise on shaoyin chapter" cloud: shaoyin disease, sore throat, fullness in chest, restlessness and restlessness, which is cooked in pork skin soup. "Yi Zong jin Jian" is a prescription: the "pig skin" is also the skin of the leather. "Li Shizhen" Ben Cao gang mu "cloud: from October to March, cattle, buffalo and donkey hide are used for the first time and pig, horse, mule and camel hide are used for the second time. "
The new donkey-hide gelatin is a new donkey-hide gelatin which is successfully developed by Shandong Pingyin donkey-hide gelatin factories in 1976 according to the records of Chinese medical heritage traditional Chinese medicine documents, solves the problem of raw material substitutes of the donkey-hide gelatin, has the same function and shape as the donkey-hide gelatin, and is named as a new product. The new donkey-hide gelatin is prepared by selecting pure pigskin as a raw material, using spring water of the Langxi river which is unique and according to the traditional gelatin preparation technology and combining with the modern scientific technology, has the efficacies of nourishing liver and kidney, enriching blood and stopping bleeding, and is widely applied to symptoms such as primary thrombocytopenia, leucopenia, uterine functional bleeding, pulmonary tuberculosis hemoptysis, epistaxis, aplastic anemia, menoxenia, blood deficiency before and after delivery and blood deficiency caused by dizziness, hypodynamia, palpitation and the like clinically.
In the prior art, the donkey-hide gelatin is recorded to have an anti-aging effect, and a reference is made to a paper (research on the anti-oxidation effect and mechanism of the donkey-hide gelatin cake and the main raw material donkey-hide gelatin [ D ]. Zhejiang university, 2019 ]), but in reality, the anti-aging effect of the donkey-hide gelatin is found to be limited in use, and the application of a composition of the donkey-hide gelatin and new donkey-hide gelatin in preparation of an anti-aging medicament is not disclosed in the prior art.
Disclosure of Invention
In order to solve the problems, the application provides an application of a composition of donkey-hide gelatin and new donkey-hide gelatin in preparing anti-aging medicaments.
Preferably, the combination of said donkey-hide gelatin with said novel donkey-hide gelatin reduces the activity of β -galactosidase.
Preferably, the donkey-hide gelatin and the new donkey-hide gelatin are included in effective dose.
Preferably, the weight ratio of the donkey-hide gelatin to the new donkey-hide gelatin is 1: 10-10: 1.
Preferably, the weight ratio of the donkey-hide gelatin to the new donkey-hide gelatin is 1: 1.
β -galactosidase is an important biological index for reaction of aging degree, after the zebra fish is treated by the composition of donkey-hide gelatin and new donkey-hide gelatin, the β -galactosidase staining result shows that the β -galactosidase activity in the zebra fish is obviously reduced, and the reduction has very significant statistical significance, the application further discloses that the concentration of the composition of donkey-hide gelatin and new donkey-hide gelatin is within the range of 10-100 mug/mL, the β -galactosidase activity in the zebra fish is reduced along with the increase of the concentration of the composition of donkey-hide gelatin and new donkey-hide gelatin, and a good decreasing relation is presented, the application obtains the effective dose of the composition of donkey-hide gelatin and new donkey-hide gelatin through experimental research and is applied to preparation of anti-aging drugs, and can further achieve better anti-aging effect by reducing the activity of β -galactosidase.
Drawings
The accompanying drawings, which are included to provide a further understanding of the application and are incorporated in and constitute a part of this application, illustrate embodiment(s) of the application and together with the description serve to explain the application and not to limit the application. In the drawings:
FIG. 1 is a graph showing the β -galactosidase staining pattern of zebrafish, wherein panel A is a graph showing the experimental results of a control group, panel B is a graph showing the experimental results of example 1, panel C is a graph showing the experimental results of example 2, and panel D is a graph showing the experimental results of example 3, wherein black arrows indicate β -galactosidase staining sites.
Detailed Description
Example 1: experimental methods
Mixing colla Corii Asini and new colla Corii Asini sample at a certain proportion, grinding into powder, and dissolving with sterile water to obtain experimental medicine.
The experimental method provided by the invention adopts healthy AB line zebra fish developing 8hpf as an experimental animal, incubates an experimental drug and an embryo for 3 days, and after the incubation is finished, uses an β -galactosidase staining kit to stain β -galactosidase in the zebra fish body, and statistically analyzes the staining intensity of the fish body.
The donkey-hide gelatin and the new donkey-hide gelatin samples are provided by Fupai donkey-hide gelatin company, the β -galactosidase staining kit is purchased from Biyuntian biotechnology company, and the AB series zebra fish is provided by a zebra fish drug screening platform of biological research institute of academy of sciences of Shandong province.
The experimental apparatus used in this example includes: model SZX16 fluorescent microscope and DP2-BSW image acquisition system (Olympus, Japan); an inverted microscope model X51 (Olympus, japan); forma3111 type water jacket CO2Incubators (Forma corporation, usa); zebra fish breeding equipment (Beijing Aisheng science and technology company).
The specific implementation process in this example is as follows:
the healthy AB-series zebra fish fertilized with 8hpf is used as an animal model, 10 embryos are tested in each example, 2 multiple wells are arranged at the same time, each example is repeated three times according to the conditions of the specific examples in the following table 1, the embryos are placed in an incubator at 28.5 ℃ for continuous treatment for 3 days (1 mL volume of new solution is changed every other day), after the treatment is finished, the zebra fish are washed by PBS buffer solution, then, the β -galactosidase in the zebra fish of each group is stained by using an β -galactosidase staining kit, the staining intensity reflects the activity of β -galactosidase in the zebra fish, then, the staining intensity is calculated by using Imagepro-plus software, and the data are statistically analyzed by using GraphPad software to evaluate the anti-aging activity of the sample.
TABLE 1 specific examples and conditions of implementation in the examples
Example 2: characterization of
The reference standard of the test method of the activity of β -galactosidase in the example is a spectrophotometric method of a GB/T33409-2016 β -galactosidase activity detection method.
TABLE 2 Effect of combination of Ejiao and New Ejiao on Zebra fish β -galactosidase Activity
From the experimental data in table 2, it can be seen that β -galactosidase activity is significantly reduced after zebrafish is treated with the combination of donkey-hide gelatin and new donkey-hide gelatin at a proper ratio and action concentration by comparing the experimental data of examples 1 to 7 with the experimental data of the control group, wherein important factors include that 1, the weight ratio of donkey-hide gelatin to new donkey-hide gelatin is controlled to be 1: 10-10: 1, and especially when the weight ratio of donkey-hide gelatin to new donkey-hide gelatin is 1:1, the effect of reducing β -galactosidase activity is optimal, and 2, the action concentration of donkey-hide gelatin to new donkey-hide gelatin is controlled to be 10-100 μ g/mL, and especially when the action concentration of the combination is 100 μ g/mL, the effect of reducing β -galactosidase activity is optimal.
Comparing example 1 with comparative example 1 and comparative example 2, it can be seen that the effect of lowering β -galactosidase activity after treating zebrafish with the combination of donkey-hide gelatin and new donkey-hide gelatin is far better than the effect of lowering β -galactosidase activity after treating zebrafish with donkey-hide gelatin alone or new donkey-hide gelatin alone under the same other conditions.
It can be seen from the comparison between example 1 and comparative example 3 and the comparison between example 3 and comparative example 4 that the concentration of the combination of donkey-hide gelatin and new donkey-hide gelatin is too low or too high, which affects the efficiency of β -galactosidase activity reduction.
In summary, β -galactosidase is an important biological indicator of the degree of aging response, after zebrafish is treated with the combination of donkey-hide gelatin and new donkey-hide gelatin, according to the β -galactosidase staining results, as shown in fig. 1, B, C, D, compared with the control group (0 μ g/mL), as shown in fig. 1, fig. a, β -galactosidase activity in zebrafish is significantly reduced, and the reduction has a very significant statistical significance, as shown in fig. 1 and table 2, the concentration of the combination of donkey-hide gelatin and new donkey-hide gelatin is in the range of 10-100 μ g/mL, and β -galactosidase activity in zebrafish is reduced with the increase of the concentration, and shows a good descending relationship.
Under the experimental condition, the application finds that the donkey-hide gelatin and new donkey-hide gelatin composition of 10-100 mug/mL can reduce the activity of β -galactosidase in zebra fish bodies, and the donkey-hide gelatin and new donkey-hide gelatin composition under each concentration has anti-aging activity.
The results show that the combination of donkey-hide gelatin and new donkey-hide gelatin can be used for preparing anti-aging medicaments, in particular anti-aging medicaments capable of reducing the activity of β -galactosidase.
The embodiments in the present specification are described in a progressive manner, and the same and similar parts among the embodiments are referred to each other, and each embodiment focuses on the differences from the other embodiments. In particular, for the system embodiment, since it is substantially similar to the method embodiment, the description is simple, and for the relevant points, reference may be made to the partial description of the method embodiment.
The above description is only an example of the present application and is not intended to limit the present application. Various modifications and changes may occur to those skilled in the art. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present application should be included in the scope of the claims of the present application.
Claims (6)
1. An application of composition of colla Corii Asini and new colla Corii Asini in preparing antiaging medicine is provided.
2. Application of a composition of colla Corii Asini and new colla Corii Asini in preparing antiaging medicine for reducing activity of β -galactosidase is provided.
3. Use according to claim 1 or 2, characterized in that: comprises effective dose of colla Corii Asini and new colla Corii Asini.
4. Use according to claim 3, characterized in that: the concentration of the composition of donkey-hide gelatin and new donkey-hide gelatin is 10-100 mug/mL.
5. Use according to claim 3, characterized in that: the weight ratio of the donkey-hide gelatin to the new donkey-hide gelatin is 1: 10-10: 1.
6. Use according to claim 5, characterized in that: the weight ratio of the donkey-hide gelatin to the new donkey-hide gelatin is 1: 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911220882.1A CN110742907A (en) | 2019-12-03 | 2019-12-03 | Application of composition of donkey-hide gelatin and new donkey-hide gelatin in preparation of anti-aging drugs |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911220882.1A CN110742907A (en) | 2019-12-03 | 2019-12-03 | Application of composition of donkey-hide gelatin and new donkey-hide gelatin in preparation of anti-aging drugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110742907A true CN110742907A (en) | 2020-02-04 |
Family
ID=69285462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911220882.1A Pending CN110742907A (en) | 2019-12-03 | 2019-12-03 | Application of composition of donkey-hide gelatin and new donkey-hide gelatin in preparation of anti-aging drugs |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110742907A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112111554A (en) * | 2020-08-31 | 2020-12-22 | 南京新环检测科技有限公司 | Method for evaluating anti-aging efficacy of cosmetics |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102552324A (en) * | 2012-02-04 | 2012-07-11 | 赵德润 | Novel technique for preparing natural donkey-hide gelatin |
| CN103816217A (en) * | 2014-03-03 | 2014-05-28 | 张江林 | A traditional Chinese medicine mixture capable of delaying skin ageing, a preparation method thereof and applications thereof |
| CN104083404A (en) * | 2014-08-01 | 2014-10-08 | 李江红 | Anti-aging traditional Chinese medicinal composition |
| CN105687243A (en) * | 2016-03-03 | 2016-06-22 | 东阿阿胶股份有限公司 | Application of donkey-hide gelatin to preparing drugs or health-care products for treating premature ovarian failure |
-
2019
- 2019-12-03 CN CN201911220882.1A patent/CN110742907A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102552324A (en) * | 2012-02-04 | 2012-07-11 | 赵德润 | Novel technique for preparing natural donkey-hide gelatin |
| CN103816217A (en) * | 2014-03-03 | 2014-05-28 | 张江林 | A traditional Chinese medicine mixture capable of delaying skin ageing, a preparation method thereof and applications thereof |
| CN104083404A (en) * | 2014-08-01 | 2014-10-08 | 李江红 | Anti-aging traditional Chinese medicinal composition |
| CN105687243A (en) * | 2016-03-03 | 2016-06-22 | 东阿阿胶股份有限公司 | Application of donkey-hide gelatin to preparing drugs or health-care products for treating premature ovarian failure |
Non-Patent Citations (2)
| Title |
|---|
| 姜 伟: "论阿胶与老年长寿 ", 《中国农村卫生》 * |
| 靳士英: "《抗衰老保健中药小百科》", 31 January 2003, 人民军医出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112111554A (en) * | 2020-08-31 | 2020-12-22 | 南京新环检测科技有限公司 | Method for evaluating anti-aging efficacy of cosmetics |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | Evaluation of decalcification techniques for rat femurs using HE and immunohistochemical staining | |
| DE69837393T2 (en) | STIMULATION OF HEMATOPOIETIC CELLS IN THE VITRO | |
| Michel et al. | Follistatins: more than follicle-stimulating hormone suppressing proteins | |
| Rabinovitch et al. | A histochemical study of" acid" and" alkaline" phosphatase distribution in normal human bone marrow smears | |
| Babitha et al. | Luteinizing hormone, insulin like growth factor-1, and epidermal growth factor stimulate vascular endothelial growth factor production in cultured bubaline granulosa cells | |
| CN1452492A (en) | Neuroprotective peptides | |
| CN110742907A (en) | Application of composition of donkey-hide gelatin and new donkey-hide gelatin in preparation of anti-aging drugs | |
| Wen et al. | Effects of primary microglia and astrocytes on neural stem cells in in vitro and in vivo models of ischemic stroke | |
| Couturier et al. | Reproducing diabetic retinopathy features using newly developed human induced‐pluripotent stem cell‐derived retinal Müller glial cells | |
| Collier et al. | Changes in insulin and somatomedin receptors and uptake of insulin, IGF-I and IGF-II during mammary growth, lactogenesis and lactation | |
| Gray et al. | Bilirubin-serum protein complexes and the van den Bergh reaction | |
| DE3600083C2 (en) | Use of alpha interferon to treat the respiratory disease complex in cattle | |
| CN106701668B (en) | Mesenchymal stem cells, method for purifying and expanding mesenchymal stem cells and application of mesenchymal stem cells | |
| CN110840916A (en) | Application of composition of donkey-hide gelatin and new donkey-hide gelatin in preparation of antioxidant drugs | |
| CN113016961A (en) | Novel biological preparation for improving immunity of broiler chickens and preparation method thereof | |
| CN110693915A (en) | Application of donkey-hide gelatin and novel donkey-hide gelatin composition in preparation of medicines for preventing or treating diseases related to leucopenia | |
| Шабунин et al. | EFFECT OF THE PROBIOTIC «CELLOBACTER IN-T» ON THE LEVEL OF GLYCOGEN IN HEPATOCITES OF THE COMMON CARP (Cyprinus carpio) | |
| CN107537025B (en) | Application of Metrnl protein or gene in regulation of antibacterial peptide expression | |
| GB2044613A (en) | Hormone composition for promoting ovulation | |
| Michal et al. | Isolation and characterization of canine satellite cells | |
| Ekfalck et al. | Presence of Receptors for Epidermal Growth Factor (EGF) in the Matrix of the Bovine Hoof—a Possible New Approach to the Laminitis Problem 1 | |
| Al-Hussaini | Alkaline phosphatase in fish gut | |
| Pesall et al. | The effect of insulin-like growth factor analogs on turkey satellite cell and embryonic myoblast proliferation | |
| Carani et al. | Histochemistry and growth characteristics of bovine semitendinosus muscle exposed to recombinant bovine somatotropin (rbST) | |
| Elokil et al. | Study the effect of microinjection of Zn, Fe, and Cu loaded in montmorillonite on development activities in fertilized chicken eggs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200204 |